Research, Industry, Medical and Scientific News

Share

Below you will find news and press releases from industry, government, and academia regarding product developments and medical/scientific research news.

drugs for overactive bladder (OAB)

Study Finds Vibegron Has No Adverse Ambulatory Effects in Patients with OAB

It is important for clinicians to perform ambulatory blood pressure monitoring (ABPM) for patients taking new prescribed medications, as they may affect blood pressure or heart rate in detrimental ways. It is especially important to monitor patients with overactive bladder (OAB), as this group has an increasing abundance of novel medicines available to them.  In a recent study presented at the 2021 American Urological Association Annual Meeting,¹ Michael A. Weber, MD, and co-authors assessed the blood pressure and heart rate profiles of the beta 3 adrenergic receptor agonist vibegron (Gemtesa) in treating patients with OAB. Read more.

Source: Urology Times, November 5 2021

Principle Business Enterprises and Elizabeth Dole Foundation Provide Relief for Hundreds of Veterans, Family Caregivers

Principle Business Enterprises, Inc., (PBE), which manufactures Tranquility® superabsorbent products, and the Elizabeth Dole Foundation, a prominent military Caregivers advocacy group, have partnered to provide Veterans and their families free in-home help. Their joint campaign themed “Relief and Freedom for Veteran Caregivers” encourages Caregivers of wounded, ill or injured service members to apply for free respite support and, for those with absorbent product needs, a customized incontinence care kit at TranquilityProducts.com/Respite. Read more.

Source: PRNewswire, November 1, 2021

product approval introduction

FDA Grants Breakthrough Device Designation to leva System for Chronic Fecal Incontinence

The FDA has granted a breakthrough device designation to the leva Digital Therapeutic System for use as a first-line treatment in women with chronic fecal incontinence (FI) in women, according to Renovia, the developer of the device. The breakthrough device designation will expedite the development and regulatory review of this treatment system in female patients with FI. Benefits of the designation include priority review from the FDA for clinical trial protocols and commercialization decisions, and potentially facilitating Medicare reimbursement if the FDA approves the device. Read more.

Source: Urology Times, November 1, 2021

business buildings

Stewartville Plant Creates New Solution to an Old Problem

Automated machines quietly raise and lower trays of liquid silicone, water and a paraffin-like material in a Stewartville facility to create a new solution to an age-old medical condition that afflicts an estimated 2 percent of the world’s population. Multiple, carefully monitored dips create trays of 400 silicone inserts with a small bubble of liquid in four minutes. The inserts then move on to packaging to eventually be shipped to Minnesota Medical Technologies’ waiting customers in a growing number of countries. Designed by and created by a local team led by brothers Jim and Philip Conway, the patented myMiracle device is a small, lubricated anal insert to be used as a simple and discreet way to treat fecal incontinence.  Read more.

Source: Post-Bulletin, Rochester, Minn., August 7, 2021

e. coli bacteria

Bladder-on-a-Chip and Bladder Organoids Reveal Dynamics of UTIs

Researchers at the Ecole Polytechnique Fédérale de Lausanne in Switzerland developed two complementary benchtop bladder models that could help in understanding the mechanisms behind recurring urinary tract infections (UTIs). The first involves bladder organoids, which allow the researchers to study bacterial-bladder cell interactions under realistic conditions, which include the 3D multi-layered architecture of the bladder wall. The second is a bladder-on-a-chip, which includes additional features that mimic the bladder environment, including the mechanical effects of bladder filling and voiding and bladder vasculature. Read more.

Source: Medgadget, August 3, 2021

product approval introduction

Tibial Nerve Stimulator Is Safe, Effective, and Durable, 12-month Data Indicate

A nickel-sized tibial nerve stimulator offers overactive bladder (OAB) patients with urgency urinary incontinence long-term outcomes comparable to other treatment options, including percutaneous tibial nerve stimulation.  Findings of a study published in Urology1 imply OAB treatment with the investigational eCoin (Valencia Technologies Corp) device is safe and achieves a durable response, says the study’s lead author, urologist Peter Gilling, MD, of Tauranga Urology Research Ltd, Tauranga, New Zealand. Read more.

Source: Urology Times, July 15, 2021

Apple iPhone

New App Supports Nurses to Provide Bladder and Bowel Continence Care

A free app that could boost nurses’ success in managing patients with bladder or bowel incontinence was launched on Monday, marking the beginning of World Continence Week. Those behind the new app said it was a result of a “genuine desire to help people with bladder and bowel symptoms access information and advice that can help”. The CONfidence app offers information, self-care tips and links to local health and support services for the estimated 14 million people in the UK with bladder control problems, and the 6.5 million who have bowel control problems. Read more.

Source: Nursing Times, June 22, 2021